- Conditions
- Sickle Cell Disease
- Interventions
- FDNIRS-DCS, MRI
- Device
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 833
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- CLN6, Batten Disease
- Interventions
- AT-GTX-501
- Genetic
- Lead sponsor
- Emily de los Reyes
- Other
- Eligibility
- 12 Months and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pitt Hopkins Syndrome
- Interventions
- MZ-1866
- Genetic
- Lead sponsor
- Mahzi Therapeutics
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Oakland, California • Aurora, Colorado • Chicago, Illinois
- Conditions
- HIV-1
- Interventions
- OZ1 transduced cells
- Genetic
- Lead sponsor
- Janssen-Cilag Pty Ltd
- Industry
- Eligibility
- Not listed
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2017
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Francisco, California • New York, New York
- Conditions
- Melanoma
- Interventions
- Temozolomide, Abraxane, Cisplatin, Interleukin-2, Interferon alpha 2b
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
- Interventions
- Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo
- Genetic · Drug
- Lead sponsor
- Helixmith Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- 4D-150 IVT, Aflibercept IVT
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 5
- States / cities
- Hagerstown, Maryland • Eugene, Oregon • Erie, Pennsylvania + 2 more
- Conditions
- Norovirus Gastroenteritis
- Interventions
- VXA-G1.1-NN Oral Vaccine
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 19 Years to 49 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
- Interventions
- CARv3-TEAM-E T cells
- Drug
- Lead sponsor
- Marcela V. Maus, M.D.,Ph.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Canavan Disease
- Interventions
- rAAV9-CB6-AspA
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Months to 24 Months · Male only
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Prostate Cancer
- Interventions
- Gene Modified T Cells
- Biological
- Lead sponsor
- Roger Williams Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Glioblastoma Multiforme, Astrocytoma, Grade III
- Interventions
- ADV/HSV-tk (gene therapy)
- Drug
- Lead sponsor
- David Baskin MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Atrial Fibrillation, Post-operative Atrial Fibrillation
- Interventions
- AdKCNH2-G628S
- Biological
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Interventions
- VV-14303
- Genetic
- Lead sponsor
- Kriya Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Chandler, Arizona • Lady Lake, Florida
- Conditions
- Hemophilia B
- Interventions
- verbrinacogene setparvovec
- Genetic
- Lead sponsor
- Spur Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan
- Conditions
- Non-small Cell Lung Cancer Stage I
- Interventions
- Ad5-yCD/mutTKSR39rep-ADP Adenovirus
- Biological
- Lead sponsor
- Benjamin Movsas, M.D.
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Sickle Cell Disease
- Interventions
- single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
- Biological
- Lead sponsor
- David Williams
- Other
- Eligibility
- 3 Years to 40 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Boston, Massachusetts
- Conditions
- Triple Negative Breast Cancer, Anthracycline-refractory TNBC
- Interventions
- Docetaxel, Pembrolizumab, IL-12 gene therapy
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Wiskott-Aldrich Syndrome
- Interventions
- Retrovirus-mediated gene transfer
- Biological
- Lead sponsor
- David Williams
- Other
- Eligibility
- 3 Months to 35 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hemoglobin Disorder
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2050
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Delandistrogene Moxeparvovec, Standard of Care
- Genetic · Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years and older · Male only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2038
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 22 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- KH631
- Drug
- Lead sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Lemont, Illinois • Boston, Massachusetts + 4 more
- Conditions
- COVID-19, SARS-CoV-2 Infection
- Interventions
- Positive for SARS-CoV-2 infection
- Diagnostic Test
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 68 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- HIV
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland